Looking in the Wrong Place: Cancer as a Clearance Failure and the Case for Psychiatry as an Oncological Discipline

Oncology has organised itself around the mutated cell. Therapies are designed against specific driver mutations, specific tissues, specific receptor profiles — and each success, however real, remains confined to the population carrying that particular lesion. This paper argues that the persistence of this pattern is not a failure of effort or intelligence but a failure of level: the field has concentrated on the event that initiates cancer while paying comparatively little attention to the system that determines whether that event survives. Somatic mutation is not rare. It is continuous and statistically inevitable, arising principally from DNA replication error across tens of billions of daily cell divisions, supplemented by chemical and radiative damage and viral integration. What is rare is a mutation that persists. Between the mutational event and clinical disease stand three universal clearance checkpoints — enzymatic DNA repair, apoptotic elimination, and immune surveillance — together with the microenvironmental conditions that any surviving clone requires to expand and disseminate. Every cancer, irrespective of tissue or mutational profile, must defeat the same checkpoints. These checkpoints are not autonomous. Each is measurably modulated by glucocorticoid and catecholamine signalling under the control of the HPA and SAM axes. This yields the paper's central proposition: cancer is more usefully modelled as a clearance failure than as a mutation event, and the principal modifiable determinant of clearance capacity is neuroendocrine state. If this is correct, a structural anomaly follows. The agents that modulate these axes sit almost entirely within psychiatry and cardiology, not oncology. The discipline that holds the relevant levers is not the discipline running the relevant trials. We argue that this gap, rather than any specific compound, is the finding of consequence, and propose falsifiable predictions by which it can be tested. This paper supersedes an earlier framework by the same author, 'The Neuroendocrine Firewall,' revising its mechanistic claims substantially.